New York, NY -- (SBWIRE) -- 01/02/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Rexahn Pharmaceuticals, Inc (NYSEMKT:RNN), Mast Therapeutics Inc (NYSEMKT:MSTX), Athersys, Inc (NASDAQ:ATHX), Eagle Bulk Shipping Inc (NASDAQ:EGLE),
Rexahn Pharmaceuticals, Inc (NYSEMKT:RNN) showed a volume of 1.49 million shares by the end of last trade whereas the average volume of the stock remained 1.59 million shares. The stock opened the session at $0.50 but then moved to $0.510. At that price, the stock showed a positive performance of 1.98%. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates,
Will RNN Continue To Move Higher? Find Out Here
Mast Therapeutics Inc (NYSEMKT:MSTX) opened the session at $0.44 and closed the session at $0.462. The stock showed a positive performance of 3.45% in previous trading session. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease.
For How Long MSTX will fight for Profitability? Read This Trend Analysis report
Athersys, Inc (NASDAQ:ATHX) opened the session at $2.43 and closed the session at $2.50. The stock showed a positive performance of 2.88% in previous trading session. The beta of the stock remained 0.63. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials. The Company’s clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.
Why Should Investors Buy ATHX After The Recent Gain? Just Go Here and Find Out
Eagle Bulk Shipping Inc (NASDAQ:EGLE) the stock advanced 10.34% and finished the session at $4.59. Traded with volume of 1.46 million shares in the prior session and the average volume of the stock remained 1.24 million shares. The beta of the stock remained 2.91. Eagle Bulk Shipping Inc. is engaged primarily in the ocean transportation of a range of major and minor bulk cargoes, including iron ore, coal, grain, cement and fertilizer, along worldwide shipping routes. The Company operates in the Handymax sector of the dry bulk industry, with particular emphasis on the Supramax class of vessels. The Company owns Supramax dry bulk vessel. Supramax dry bulk vessels range in size from 50,000 to 60,000 deadweight tons.
Will EGLE Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)